Perspectives on the failure of pharmaceutical and medical device industries to fully protect public health interests.

[1]  V L Gott,et al.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. , 1980, The New England journal of medicine.

[2]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[3]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[4]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[5]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[6]  E. Topol,et al.  A coxib a day won't keep the doctor away , 2004, The Lancet.

[7]  R. Steinbrook.  The controversy over Guidant's implantable defibrillators. , 2005, The New England journal of medicine.

[8]  Barry Meier,et al.  Maker of heart device kept flaw from doctors. , 2005, The New York times on the Web.

[9]  W. Roberts,et al.  The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk. , 2005, The American journal of cardiology.

[10]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[11]  B. Maron,et al.  Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. , 2005, Heart rhythm.

[12]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[13]  Jeffrey M Drazen,et al.  Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. , 2005, The New England journal of medicine.

[14]  B. Lindsay,et al.  Life-threatening malfunction of implantable cardiac devices. , 2006, The New England journal of medicine.

[15]  Maggie Mahar,et al.  Money-Driven Medicine: The Real Reason Health Care Costs So Much , 2006 .

[16]  I. Zarraga,et al.  Coxibs and heart disease: what we have learned and what else we need to know. , 2007, Journal of the American College of Cardiology.